RRM1 and non-small cell lung carcinoma: In earlier retrospective studies[8], [9], we found that high levels of RRM1 predicted longer survival in stage IV NSCLC patients treated with gemcitabine plus cisplatin but not in those treated with cisplatin-based regimens without gemcitabine.